Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 2Carcinoma 2Urinary Incontinence 1Squamous Cell Carcinoma of Head and Neck 1Pyridoxine-dependent epilepsy 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Erectile Dysfunction 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

pembrolizumab 2enfortumab vedotin 2Tablets 2Exercise 2Acupuncture Therapy 2nicotinamide-beta-riboside 1Vitamin B Complex 1Thioctic Acid 1Tadalafil 1Single Person 1Rosuvastatin Calcium 1Omeprazole 1Memantine 1Massage 1Lenalidomide 1Gloves, Surgical 1Fish Oils 1Fenofibrate 1Exercise Therapy 1Dexamethasone 1Cryotherapy 1Corn Oil 1Control Groups 1Bortezomib 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × Tadalafil × 1 year × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡